Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: palomera l. Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241. Blood. 2019. PMID: 31484647 Free PMC article. Clinical Trial.
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
San Miguel JF, Almeida J, Mateo G, Bladé J, López-Berges C, Caballero D, Hernández J, Moro MJ, Fernández-Calvo J, Díaz-Mediavilla J, Palomera L, Orfao A. San Miguel JF, et al. Among authors: palomera l. Blood. 2002 Mar 1;99(5):1853-6. doi: 10.1182/blood.v99.5.1853. Blood. 2002. PMID: 11861305 Free article.
Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
Lahuerta JJ, Grande C, Blade J, Martínez-López J, de la Serna J, Alegre A, Garcia LJ, Caballero D, de la Rubia J, Marín J, Perez-Lopez C, Sureda A, Escudero A, Cabrera R, Conde E, García-Ruiz JC, Pérez-Equiza K, Hernandez F, Palomera L, León A, Giraldo P, Solano C, Bargay J, San MJ; Spanish Multiple Myeloma Group. Lahuerta JJ, et al. Among authors: palomera l. Leuk Lymphoma. 2002 Jan;43(1):67-74. doi: 10.1080/10428190210194. Leuk Lymphoma. 2002. PMID: 11908738
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
San Miguel JF, Lahuerta JJ, García-Sanz R, Alegre A, Bladé J, Martinez R, García-Laraña J, De La Rubia J, Sureda A, Vidal MJ, Escudero A, Pérez-Esquiza E, Conde E, García-Ruiz JC, Cabrera R, Caballero D, Moraleda JM, Leon A, Besalduch J, Hernandez MT, Rifon J, Hernandez F, Solano C, Palomera L, Parody R, Gonzalez JD, Mataix R, Maldonado J, Constela J, Carrera D, Bello JL, De Pablos JM, Pérez-Simón JA, Torres JP, Olanguren J, Prieto E, Acebede G, Peñarrubia MJ, Torres P, Díez-Martín JL, Rivas A, Sánchez JM, Díaz-Mediavilla J. San Miguel JF, et al. Among authors: palomera l. Hematol J. 2000;1(1):28-36. doi: 10.1038/sj.thj.6200003. Hematol J. 2000. PMID: 11920166
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
García-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, López R, Grande-García C, Alegre A, Vargas-Pabón M, Gutiérrez ON, Rodríguez JA, San Miguel JF. García-Sanz R, et al. Among authors: palomera l. Leukemia. 2004 Apr;18(4):856-63. doi: 10.1038/sj.leu.2403322. Leukemia. 2004. PMID: 14973508 Clinical Trial.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). Bladé J, et al. Among authors: palomera l. Blood. 2005 Dec 1;106(12):3755-9. doi: 10.1182/blood-2005-03-1301. Epub 2005 Aug 16. Blood. 2005. PMID: 16105975 Free article. Clinical Trial.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: palomera l. Blood. 2006 Oct 1;108(7):2165-72. doi: 10.1182/blood-2006-04-019778. Epub 2006 Jun 13. Blood. 2006. PMID: 16772605 Free article. Clinical Trial.
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, Carrera D, Rosiñol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernández-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF; GEM/PETHEMA Spanish Group. Gutiérrez NC, et al. Among authors: palomera l. Leukemia. 2007 Jan;21(1):143-50. doi: 10.1038/sj.leu.2404413. Epub 2006 Oct 5. Leukemia. 2007. PMID: 17024116 Clinical Trial.
The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.
Sarasquete ME, García-Sanz R, Armellini A, Fuertes M, Martín-Jiménez P, Sierra M, Del Carmen Chillón M, Alcoceba M, Balanzategui A, Ortega F, Hernández JM, Sureda A, Palomera L, González M, San Miguel JF. Sarasquete ME, et al. Among authors: palomera l. Haematologica. 2006 Nov;91(11):1551-4. Epub 2006 Oct 17. Haematologica. 2006. PMID: 17043023
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: palomera l. Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5. Haematologica. 2008. PMID: 18322252 Free article. Clinical Trial.
141 results